🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Paliperidone palmitate

    Janssen Cilag International NV

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  2. Palliative Chemotherapy

    Sun Yat-sen University

    Colorectal Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  3. Paracetamol/Ibuprofen Vale 1000 mg/300 mg oldatos infúzió

    Lacuna Pharma Pty Ltd

    Acute pain

    phase 3 small molecule active

    1 trial

  4. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis

    phase 3 small molecule completed

    1 trial

  5. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Familial

    phase 3 small molecule completed

    1 trial

  6. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Hereditary

    phase 3 small molecule completed

    1 trial

  7. Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins, Peanut food challenge, oral paste “placebo” - Placebo formulation, Soluprick Positive control, 10 mg/ml, Solution for skin-prick test, Viaskin Peanut, Soluprick Negative control, Solution for skin prick test, ALK 762 Jordnød, Opløsning til priktest (Soluprick), Nøddeallergen, The DBV712 Placebo Patch is the same system as DBV712 250 mcg Patch but without peanut proteins, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  8. Peanut food challenge, oral paste “placebo” - Placebo formulation, Viaskin Peanut, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut proteins, Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  9. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    2 trials

  10. Pegcetacoplan

    Apellis Europe B.V.

    Delayed Graft Function

    phase 3 small molecule active

    1 trial

  11. Pegcetacoplan

    Apellis Europe B.V.

    PNH

    phase 3 small molecule active

    2 trials

  12. Pegcetacoplan

    Apellis Europe B.V.

    C3G

    phase 3 small molecule active

    3 trials

  13. Pegtibatinase, 0.9 % sodium chloride saline solution (NaCL)

    Travere Therapeutics

    Classical Homocystinuria

    phase 3 small molecule active

    1 trial

  14. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial

  15. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 mab completed

    1 trial

  16. Pegylated Interferon Alfa-2a

    Hoffmann-La Roche

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  17. Pelacarsen

    Novartis Pharmaceuticals

    Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  18. Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  19. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Gastric Neoplasms

    phase 3 mab completed

    1 trial

  20. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Endometrial Neoplasms

    phase 3 mab active

    1 trial

  21. Pembrolizumab

    Eisai Co.,

    Endometrial Neoplasms

    phase 3 small molecule completed

    1 trial

  22. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Triple Negative Breast Neoplasms

    phase 3 mab completed

    1 trial

  23. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Urinary Bladder Neoplasms

    phase 3 small molecule active

    1 trial

  24. Pembrolizumab/Vibostolimab

    Merck KGaA, Darmstadt, Germany

    Lung Neoplasms

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources